Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Year Later, Indian Import Duties Still In Place On Cancer Drugs

This article was originally published in PharmAsia News

Executive Summary

Import duties still in place in India on the most promising cancer drugs are keeping the price to Indians at about 35 percent more than prices charged elsewhere in the world. The import duties were to have been lifted early last year on certain life-saving drugs, but red tape apparently has delayed the exemptions. A Finance Ministry official said the agency still had not received a recommendation from the Health Ministry for drugs to be placed on a list of exempted drugs. The government had listed 14 cancer drugs that were supposed to be exempt from countervailing duties and have import duties reduced to 5 percent. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel